Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer across distinct immunohistochemistry statuses
Translational Breast Cancer Research · 2025-07 · 6 · 22-22
DOI: 10.21037/tbcr-25-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Breast Cancer Research, 2025-07. Verfasst von Song Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Oncology, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Breast Oncology, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, China.
ORCID-Profile: Song Wu
Zitieren
APA
Wu, S., Li, J., Bian, L., Zhang, S., Zhang, S., Wang, T., & Jiang, Z. (2025). Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer across distinct immunohistochemistry statuses. Translational Breast Cancer Research, 6, 22-22. https://doi.org/10.21037/tbcr-25-8
Vancouver
Wu S, Li J, Bian L, Zhang S, Zhang S, Wang T, et al. Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer across distinct immunohistochemistry statuses. Translational Breast Cancer Research. 2025;6:22-22. doi:10.21037/tbcr-25-8
BibTeX
@article{Wu2025,
author = {Wu, Song and Li, Jianbin and Bian, Li and Zhang, Siyuan and Zhang, Shaohua and Wang, Tao and Jiang, Zefei},
title = {Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer across distinct immunohistochemistry statuses},
journal = {Translational Breast Cancer Research},
year = {2025},
volume = {6},
pages = {22--22},
doi = {10.21037/tbcr-25-8}
}
EUVIMED